Status:
NOT_YET_RECRUITING
Anti-phospolipid Antibodies in Lyme Borreliosis
Lead Sponsor:
University Medical Centre Ljubljana
Conditions:
Patients With Different Manifestations of Lyme Borreliosis
Persons With Nonspecific Symptoms and Positive Borrelia Antibodies in Serum
Eligibility:
All Genders
18+ years
Brief Summary
Background Lyme borreliosis, caused by Borrelia burgdorferi sensu lato is transmitted to humans through the bite of an infected Ixodes tick. B. burgdorferi sensu lato accumulates intact phospholipids ...
Eligibility Criteria
Inclusion
- Fulfillment of clinical case definition criteria for European Lyme borreliosis (doi: 10.1111/j.1469-0691.2010.03175.x.).
Exclusion
- Autoimmune diseases, acute myocardial infarction, acute deep vein thrombosis, pregnancy, syphilis.
Key Trial Info
Start Date :
May 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 15 2026
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06929546
Start Date
May 15 2025
End Date
July 15 2026
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Ljubljana
Ljubljana, Slovenia, 1525